NTRK1 and B-cell chronic lymphocytic leukemia: The receptor tyrosine kinase ROR1 has been shown to play a role in therapeutical efficiency in treatments for CLL and multiple solid tumors and immunotherapy targeting ROR1 has showed significant improvements in preclinical and clinical studies [23].